sales@fnfresearch.comTel: +86 21 80360450 | USA: +1-347-989-3985

Search Market Research Report

Home / Healthcare / Non-Insulin Therapies for Diabetes

Healthcare /

Non-Insulin Therapies for Diabetes Market – By Product (Oral and Injectable) and By Distributor (Hospital Pharmacy, Retail Pharmacies, Online Pharmacy, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2019 – 2027

  • Publish On: Sep-2019
  • Total Pages: 110
  • Report Code: FAF-46
  • Base Year: 2018
  • Format:

Industry Insights

The report covers the forecast and analysis of the non-insulin therapies for diabetes market on a global and regional level. The study provides historical data from 2015 to 2018 along with a forecast from 2019 to 2027 based on revenue (USD Million). The study includes drivers and restraints of the non-insulin therapies for diabetes market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the non-insulin therapies for diabetes market on a global level.

In order to give the users of this report a comprehensive view of the airport logistics systems market, we have included a competitive landscape and an analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are benchmarked based on their market size, growth rate, and general attractiveness.

The report provides company market share analysis to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new service launches, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the market on a global and regional basis.

The study provides a decisive view of the non-insulin therapies for diabetes market by segmenting the market based on the product, distributor, and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2019 to 2027. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

Production of novel non-insulin diabetes drugs like thiazolidinediones, glucagon-like peptide 1 analogs, dipeptidyl peptidase-4 inhibitors, and glinides for treating diabetes will propel the market expansion during the period from 2019 to 2027. Rising insulin costs will further steer the growth of the non-insulin therapies for the diabetes industry over the forecast timeline. Apart from this, the strict laws pertaining to the manufacturing of new drugs for treating diabetes can retard the market progression over the forecast period. In addition to this, the long process of approving of the drugs may further inhibit the market surge over the forecast timeframe.

Based on the product type, the market is divided into oral and injectable products. On the basis of the distributor, the industry can be classified into hospital pharmacy, online pharmacy, retail pharmacies, and others.

The key players in this market are 3SBio Group, Alkem Labs., Eli Lilly and Company, Emisphere Technologies, Eurofarma Laboratórios S.A., GEROPHARM, GlaxoSmithKline plc., Intarcia Therapeutics, Inc., Jiangsu Hengrui Medicine, Luye Pharma Group, Merck Sharp & Dohme Corp. (subsidiary of Merck & Co., Inc), Novo Nordisk, Pfizer Inc., Servier, Sumitomo Dainippon Pharma Co., Ltd., Ildong, and Syneos Health.

Table of Content

  • Chapter 1. Executive Summary 22
  • Chapter 2. Non- Insulin Therapies for Diabetes market – Product Analysis 24
    • 2.1. Global Non- Insulin Therapies for Diabetes Market – Product Overview 24
    • 2.2. Global Non- Insulin Therapies for Diabetes Market Share, by Product, 2018 & 2025 (USD Million) 24
    • 2.3. Oral 26
      • 2.3.1. Global Oral Non- Insulin Therapies for Diabetes Market, 2015-2027 (USD Million) 26
    • 2.4. Injectable 27
      • 2.4.1. Global Injectable Non- Insulin Therapies for Diabetes Market, 2015-2027 (USD Million)  27
  • Chapter 3. Non- Insulin Therapies for Diabetes market – Distributor Analysis 27
    • 3.1. Global Non- Insulin Therapies for Diabetes Market – Distributor Overview 27
    • 3.2. Global Non- Insulin Therapies for Diabetes Market Share, by Distributor, 2018 & 2025 (USD Million) 28
    • 3.3. Hospital Pharmacy 29
      • 3.3.1. Global Hospital Pharmacy Non- Insulin Therapies for Diabetes Market, 2015-2027 (USD Million) 29
    • 3.4. Retail Pharmacies 30
      • 3.4.1. Global Retail Pharmacies Non- Insulin Therapies for Diabetes Market, 2015-2027 (USD Million) 30
    • 3.5. Online Pharmacy 31
      • 3.5.1. Global Online Pharmacy Non- Insulin Therapies for Diabetes Market, 2015-2027 (USD Million) 31
    • 3.6. Others 32
      • 3.6.1. Global Others Non- Insulin Therapies for Diabetes Market, 2015-2027 (USD Million)   32
  • Chapter 4. Non- Insulin Therapies for Diabetes market – Regional Analysis 33
    • 4.1. Global Non- Insulin Therapies for Diabetes Market Regional Overview 33
    • 4.2. Global Non- Insulin Therapies for Diabetes Market Share, by Region, 2018 & 2025 (Value) 33
    • 4.3. North America 35
      • 4.3.1. North America Non- Insulin Therapies for Diabetes Market size and forecast, 2015-2027  35
      • 4.3.2. North America Non- Insulin Therapies for Diabetes Market, by Country, 2018 & 2025 (USD Million) 35
      • 4.3.3. North America Non- Insulin Therapies for Diabetes Market, by Product, 2015-2027   37
        • 4.3.3.1. North America Non- Insulin Therapies for Diabetes Market, by Product, 2015-2027 (USD Million) 37
      • 4.3.4. North America Non- Insulin Therapies for Diabetes Market, by Distributor, 2015-2027  38
        • 4.3.4.1. North America Non- Insulin Therapies for Diabetes Market, by Distributor, 2015-2027 (USD Million) 38
      • 4.3.5. U.S.  39
        • 4.3.5.1. U.S. Market size and forecast, 2015-2027 (USD Million) 39
      • 4.3.6. Canada  40
        • 4.3.6.1. Canada Market size and forecast, 2015-2027 (USD Million) 40
      • 4.3.7. Mexico  41
        • 4.3.7.1. Mexico Market size and forecast, 2015-2027 (USD Million) 41
    • 4.4. Europe 42
      • 4.4.1. Europe Non- Insulin Therapies for Diabetes Market size and forecast, 2015-2027 42
      • 4.4.2. Europe Non- Insulin Therapies for Diabetes Market, by Country, 2018 & 2025 (USD Million)  42
      • 4.4.3. Europe Non- Insulin Therapies for Diabetes Market, by Product, 2015-2027 44
        • 4.4.3.1. Europe Non- Insulin Therapies for Diabetes Market, by Product, 2015-2027 (USD Million) 44
      • 4.4.4. Europe Non- Insulin Therapies for Diabetes Market, by Distributor, 2015-2027 45
        • 4.4.4.1. Europe Non- Insulin Therapies for Diabetes Market, by Distributor, 2015-2027 (USD Million) 45
      • 4.4.5. Germany  46
        • 4.4.5.1. Germany Market size and forecast, 2015-2027 (USD Million) 46
      • 4.4.6. France  47
        • 4.4.6.1. France Market size and forecast, 2015-2027 (USD Million) 47
      • 4.4.7. U.K.  48
        • 4.4.7.1. U.K. Market size and forecast, 2015-2027 (USD Million) 48
      • 4.4.8. Italy  49
        • 4.4.8.1. Italy Market size and forecast, 2015-2027 (USD Million) 49
      • 4.4.9. Spain  50
        • 4.4.9.1. Spain Market size and forecast, 2015-2027 (USD Million) 50
      • 4.4.10. Nordic Countries 51
        • 4.4.10.1. Nordic Countries Market size and forecast, 2015-2027 (USD Million) 51
      • 4.4.11. Benelux Union 52
        • 4.4.11.1. Benelux Union Market size and forecast, 2015-2027 (USD Million) 52
      • 4.4.12. Rest of Europe 53
        • 4.4.12.1. Rest of Europe Market size and forecast, 2015-2027 (USD Million) 53
    • 4.5. Asia Pacific 54
      • 4.5.1. Asia Pacific Non- Insulin Therapies for Diabetes Market size and forecast, 2015-2027  54
      • 4.5.2. Asia Pacific Non- Insulin Therapies for Diabetes Market, by Country, 2018 & 2025 (USD Million) 54
      • 4.5.3. Asia Pacific Non- Insulin Therapies for Diabetes Market, by Product, 2015-2027 56
        • 4.5.3.1. Asia Pacific Non- Insulin Therapies for Diabetes Market, by Product, 2015-2027 (USD Million) 56
      • 4.5.4. Asia Pacific Non- Insulin Therapies for Diabetes Market, by Distributor, 2015-2027   57
        • 4.5.4.1. Asia Pacific Non- Insulin Therapies for Diabetes Market, by Distributor, 2015-2027 (USD Million) 57
      • 4.5.5. China  58
        • 4.5.5.1. China Market size and forecast, 2015-2027 (USD Million) 58
      • 4.5.6. Japan  59
        • 4.5.6.1. Japan Market size and forecast, 2015-2027 (USD Million) 59
      • 4.5.7. India  60
        • 4.5.7.1. India Market size and forecast, 2015-2027 (USD Million) 60
      • 4.5.8. New Zealand 61
        • 4.5.8.1. New Zealand Market size and forecast, 2015-2027 (USD Million) 61
      • 4.5.9. Australia  62
        • 4.5.9.1. Australia Market size and forecast, 2015-2027 (USD Million) 62
      • 4.5.10. South  Korea 63
        • 4.5.10.1. South  Korea Market size and forecast, 2015-2027 (USD Million) 63
      • 4.5.11. South-East Asia 64
        • 4.5.11.1. South-East Asia Market size and forecast, 2015-2027 (USD Million) 64
      • 4.5.12. Rest of Asia Pacific 65
        • 4.5.12.1. Rest of Asia Pacific Market size and forecast, 2015-2027 (USD Million) 65
    • 4.6. Latin America 66
      • 4.6.1. Latin America Non- Insulin Therapies for Diabetes Market size and forecast, 2015-2027  66
      • 4.6.2. Latin America Non- Insulin Therapies for Diabetes Market, by Country, 2018 & 2025 (USD Million) 66
      • 4.6.3. Latin America Non- Insulin Therapies for Diabetes Market, by Product, 2015-2027 68
        • 4.6.3.1. Latin America Non- Insulin Therapies for Diabetes Market, by Product, 2015-2027 (USD Million) 68
      • 4.6.4. Latin America Non- Insulin Therapies for Diabetes Market, by Distributor, 2015-2027  69
        • 4.6.4.1. Latin America Non- Insulin Therapies for Diabetes Market, by Distributor, 2015-2027 (USD Million) 69
      • 4.6.5. Brazil  70
        • 4.6.5.1. Brazil Market size and forecast, 2015-2027 (USD Million) 70
      • 4.6.6. Argentina  71
        • 4.6.6.1. Argentina Market size and forecast, 2015-2027 (USD Million) 71
      • 4.6.7. Rest of Latin America 72
        • 4.6.7.1. Rest of Latin America Market size and forecast, 2015-2027 (USD Million) 72
    • 4.7. The Middle-East and Africa 73
      • 4.7.1. The Middle-East and Africa Non- Insulin Therapies for Diabetes Market size and forecast, 2015-2027 73
      • 4.7.2. The Middle-East and Africa Non- Insulin Therapies for Diabetes Market, by Country, 2018 & 2025 (USD Million) 73
      • 4.7.3. The Middle-East and Africa Non- Insulin Therapies for Diabetes Market, by Product, 2015-2027  75
        • 4.7.3.1. The Middle-East and Africa Non- Insulin Therapies for Diabetes Market, by Product, 2015-2027 (USD Million) 75
      • 4.7.4. The Middle-East and Africa Non- Insulin Therapies for Diabetes Market, by Distributor, 2015-2027 76
        • 4.7.4.1. The Middle-East and Africa Non- Insulin Therapies for Diabetes Market, by Distributor, 2015-2027 (USD Million) 76
      • 4.7.5. Saudi Arabia 77
        • 4.7.5.1. Saudi Arabia Market size and forecast, 2015-2027 (USD Million) 77
      • 4.7.6. UAE  78
        • 4.7.6.1. UAE Market size and forecast, 2015-2027 (USD Million) 78
      • 4.7.7. Egypt  79
        • 4.7.7.1. Egypt Market size and forecast, 2015-2027 (USD Million) 79
      • 4.7.8. Kuwait  80
        • 4.7.8.1. Kuwait Market size and forecast, 2015-2027 (USD Million) 80
      • 4.7.9. South Africa 81
        • 4.7.9.1. South Africa Market size and forecast, 2015-2027 (USD Million) 81
      • 4.7.10. Rest of Middle-East Africa 82
        • 4.7.10.1. Rest of Middle-East Africa Market size and forecast, 2015-2027 (USD Million) 82
  • Chapter 5. Non- Insulin Therapies for Diabetes market – Competitive Landscape 83
    • 5.1. Competitor Market Share – Revenue 83
    • 5.2. Market Concentration Rate Analysis, Top 3 and Top 5 Players 85
    • 5.3. Strategic Development 86
      • 5.3.1. Acquisitions and Mergers 86
      • 5.3.2. New Products 86
      • 5.3.3. Research & Development Activities 86
  • Chapter 6. Company Profiles 87
    • 6.1. 3SBio Group 87
      • 6.1.1. Company Overview 87
      • 6.1.2. 3SBio Group Revenue and Gross Margin 87
      • 6.1.3. Product portfolio 88
      • 6.1.4. Recent initiatives 89
    • 6.2. Alkem Labs. 89
      • 6.2.1. Company Overview 89
      • 6.2.2. Alkem Labs. Revenue and Gross Margin 89
      • 6.2.3. Product portfolio 90
      • 6.2.4. Recent initiatives 91
    • 6.3. Eli Lilly and Company 91
      • 6.3.1. Company Overview 91
      • 6.3.2. Eli Lilly and Company Revenue and Gross Margin 91
      • 6.3.3. Product portfolio 92
      • 6.3.4. Recent initiatives 93
    • 6.4. Emisphere Technologies 93
      • 6.4.1. Company Overview 93
      • 6.4.2. Emisphere Technologies Revenue and Gross Margin 93
      • 6.4.3. Product portfolio 94
      • 6.4.4. Recent initiatives 95
    • 6.5. GEROPHARM 95
      • 6.5.1. Company Overview 95
      • 6.5.2. GEROPHARM Revenue and Gross Margin 95
      • 6.5.3. Product portfolio 96
      • 6.5.4. Recent initiatives 97
    • 6.6. Eurofarma Laboratórios S.A. 97
      • 6.6.1. Company Overview 97
      • 6.6.2. Eurofarma Laboratórios S.A. Revenue and Gross Margin 97
      • 6.6.3. Product portfolio 98
      • 6.6.4. Recent initiatives 99
    • 6.7. GlaxoSmithKline plc. 99
      • 6.7.1. Company Overview 99
      • 6.7.2. GlaxoSmithKline plc. Revenue and Gross Margin 99
      • 6.7.3. Product portfolio 100
      • 6.7.4. Recent initiatives 101
    • 6.8. Intarcia Therapeutics 101
      • 6.8.1. Company Overview 101
      • 6.8.2. Intarcia Therapeutics Revenue and Gross Margin 101
      • 6.8.3. Product portfolio 102
      • 6.8.4. Recent initiatives 103
    • 6.9. Jiangsu Hengrui Medicine 103
      • 6.9.1. Company Overview 103
      • 6.9.2. Jiangsu Hengrui Medicine Revenue and Gross Margin 103
      • 6.9.3. Product portfolio 104
      • 6.9.4. Recent initiatives 105
    • 6.10. Luye Pharma Group 105
      • 6.10.1. Company Overview 105
      • 6.10.2. Luye Pharma Group Revenue and Gross Margin 105
      • 6.10.3. Product portfolio 106
      • 6.10.4. Recent initiatives 107
    • 6.11. Merck Sharp & Dohme Corp. 107
      • 6.11.1. Company Overview 107
      • 6.11.2. Merck Sharp & Dohme Corp. Revenue and Gross Margin 107
      • 6.11.3. Product portfolio 108
      • 6.11.4. Recent initiatives 109
    • 6.12. Novo Nordisk 109
      • 6.12.1. Company Overview 109
      • 6.12.2. Novo Nordisk Revenue and Gross Margin 109
      • 6.12.3. Product portfolio 110
      • 6.12.4. Recent initiatives 111
    • 6.13. Pfizer Inc. 111
      • 6.13.1. Company Overview 111
      • 6.13.2. Pfizer Inc. Revenue and Gross Margin 111
      • 6.13.3. Product portfolio 112
      • 6.13.4. Recent initiatives 113
    • 6.14. Servier 113
      • 6.14.1. Company Overview 113
      • 6.14.2. Servier Revenue and Gross Margin 113
      • 6.14.3. Product portfolio 114
      • 6.14.4. Recent initiatives 115
    • 6.15. Sumitomo Dainippon Pharma Co.,Ltd. 115
      • 6.15.1. Company Overview 115
      • 6.15.2. Sumitomo Dainippon Pharma Co.,Ltd. Revenue and Gross Margin 115
      • 6.15.3. Product portfolio 116
      • 6.15.4. Recent initiatives 117
    • 6.16. Ildong 117
      • 6.16.1. Company Overview 117
      • 6.16.2. Ildong Revenue and Gross Margin 117
      • 6.16.3. Product portfolio 118
      • 6.16.4. Recent initiatives 119
    • 6.17. Syneos Health 119
      • 6.17.1. Company Overview 119
      • 6.17.2. Syneos Health Revenue and Gross Margin 119
      • 6.17.3. Product portfolio 120
      • 6.17.4. Recent initiatives 121
  • Chapter 7. Non- Insulin Therapies for Diabetes — Industry Analysis 122
    • 7.1. Non- Insulin Therapies for Diabetes Market – Key Trends 122
      • 7.1.1. Market Drivers 123
      • 7.1.2. Market Restraints 123
      • 7.1.3. Market Opportunities 124
    • 7.2. Value Chain Analysis 125
    • 7.3. Technology Roadmap and Timeline 126
    • 7.4. Non- Insulin Therapies for Diabetes Market – Attractiveness Analysis 127
      • 7.4.1. By Product  127
      • 7.4.2. By Distributor 127
      • 7.4.3. By Region  129
  • Chapter 8. Marketing Strategy Analysis, Distributors 130
    • 8.1. Marketing Channel 130
    • 8.2. Direct Marketing 131
    • 8.3. Indirect Marketing 131
    • 8.4. Marketing Channel Development Trend 131
    • 8.5. Economic/Political Environmental Change 132
  • Chapter 9. Report Conclusion 133
  • Chapter 10. Research Approach & Methodology 134
    • 10.1. Report Description 134
    • 10.2. Research Scope 135
    • 10.3. Research Methodology 135
      • 10.3.1. Secondary Research 136
      • 10.3.2. Primary Research 137
      • 10.3.3. Models  138
        • 10.3.3.1. Company Share Analysis Model 138
        • 10.3.3.2. Revenue Based Modeling 139
        • 10.3.3.3. Research Limitations 139

Industry Major Market Players

Safe and Secure SSL Encrypted

Choose License Type  

Inquiry For Buying
Facts & Factors provides an array of marketing and business research solutions distinctly designed by our expertise for the clients.
Copyright © 2019 Facts & Factors. All Rights Reserved. Sitemap - Privacy Policy - Terms & Conditions